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Background: The appropriate use criteria (AUC) for PCI were developed in order to
deliver high-quality care; however, the prognostic impact of these criteria remains
undefined. We aimed to assess the prognostic implication of the AUC for PCI in a cohort
of non-ACS patients.
Methods: Consecutive patients (n3,819) undergoing PCI at MedStar Washington
Hospital Center since the 2009 AUC publication were retrospectively grouped according
to AUC as an “appropriate”, “inappropriate” or “undetermined” indication for PCI.
Outcomes up to 1 year were compared.
Results: PCI was categorized as “appropriate” in 39%, “inappropriate” in 3.5% and as
“undetermined” in 57.5% of the patients. “Appropriate” PCI patients had a higher
prevalence of risk factors for CAD. “Inappropriate” PCI involved the treatment of more
complicated lesions, with lower rates of drug-eluting stent utilization. While there were no
differences in procedural complications among the 3 groups, the in-hospital outcome was
worse for “inappropriate” PCI patients. The 30-day and 1-year major adverse cardiac
event rates of the “appropriate”, “inappropriate” and “undetermined” PCI patients,
respectively, were comparable.(Table) In multivariable analysis, the procedural appropri-
ateness was not associated either with in-hospital or 1-year with outcome.
Conclusions: In general, physicians practicing in tertiary centers adhere to the AUC
when subjecting patients with non ACS to revascularization. The utility of the AUC to
determine long-term outcome should be challenged, and until demonstrated in prospective
clinical trials should remain a recommendation only.
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Background: Distal anastomotic lesions are the most common reason for venous graft
failure, especially early after bypass surgery. However, the best percutaneous method for
treating these lesions is still controversial.
Methods: All patients who underwent percutaneous coronary intervention (PCI) either
with balloon angioplasty alone, bare-metal stent or drug-eluting stent of distal anastomotic
lesions of the bypass grafts were retrospectively enrolled.Baseline clinical and angio-
graphic characteristics were compared, as were procedural success and clinical outcomes
at 1 year.
Results: Among the 135 lesions included in the analysis, 27 (20%) were treated with
plain old balloon angioplasty (POBA), 63 (46.7%) with a bare metal stent (BMS), and 45
(33.3%) with a drug-eluting stent (DES). The baseline characteristics were generally
comparable among the 3 groups except for more peripheral vascular disease in the BMS
group than in the POBA and DES groups (42.2% vs. 26.9% vs. 15.9%, respectively;
p0.013). More patients were admitted with acute myocardial infarction in the POBA
group than in the BMS and DES groups (26.9% vs. 9% vs. 24.4%, respectively;
p0.038). At 6 months’ follow-up, the highest rate of TLR-MACE was seen in the BMS











(95.6%) (97.8%) (92.3%) 0.056
6 months follow-up
TLR MACE 11 (16.2%) 1 (2.2%) 1 (3.8%) 0.030
TVR MACE 12 (17.6%) 3 (6.7%) 3 (11.5%) 0.276
Death 8 (10.8%) 1 (2.1%) 0 (0.0%) 0.061
TLR 2 (2.9%) 1 (2.1%) 1 (3.0%) 1.000
TVR 2 (2.9%) 2 (4.3%) 1(3.0%) 1.000
QWMI 0 (0.0%) 0 (0.0%) 0 (0.0%) 0
NQWMI 1 (1.4%) 2 (4.3%) 0 (0.0%) 0.453
ST 1 (1.4%) 1 (2.1%) 0 (0.0%) 1.000
1 year follow-up
TLR MACE 14 (20.6%) 5 (11.1%) 3 (11.1%) 0.195
TVR MACE 16 (23.5%) 8 (17.8%) 5 (18.5%) 0.604
Death 9 (13.2%) 2 (4.4%) 0 (0.0%) 0.077
TLR 4 (4.8%) 3 (6.7%) 1 (3.7%) 0.738
TVR 3 (4.8%) 4(8.9%) 1 (3.7%) 0.848
QWMI 0 (0.0%) 2 (4.4%) 0 (0.0%) 0.148
NQWMI 2 (3.2%) 2 (4.4%) 1 (3.8%) 1.000
ST 1 (1.5%) 1 (2.2%) 0 (0.0%) 1.000
TVR target vessel revascularization; MACE major adverse cardiovascular event; TLR target
lesion revascularization; QWMI Q-wave myocardial infarction; NQWMI non Q-wave myocardial
infarction; ST stent thrombosis.
Conclusions: Percutaneous revascularization of the saphenous vein graft distal anasto-
mosis site by DES implantation can be performed with a high procedural success and
favorable long-term outcomes. However, POBA is an alternative for patients who cannot
tolerate prolonged dual antiplatelet therapy.
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Background: Stent thrombosis (ST) frequently presents as an acute event triggering
myocardial infarction (MI) or death. Given the low ST event rates, single-center studies
are limited when evaluating this phenomenon. It is important to understand the factors
predicting ST and to define which patients are at high risk. This registry aims to evaluate
predictors and outcome of late drug-eluting stent (DES) ST.
Methods: 982 patients, 491 case-control pairs, from 21 sites from the USA, Canada and
Switzerland were enrolled into this multi-center, observational, case-control study of
definite, late, or very late ST in patients with DES. Cases are identified by presentation
with definite ST (ARC definition). Controls were matched according to three criteria:
same enrolling institute, date of initial DES implant, and no known history of ST. Off-line
quantitative coronary angiography (QCA) analysis was performed on the thrombotic
lesion and the control lesions for a subset of 378 case-control pairs.
Results: The average time from DES implant to ST was 897.68  652.82 days. The
average lesion length was significantly longer for the ST patients compared to control.
There were more LCX and bypass graft lesions and thrombus upon DES implant in the
ST group. The stented segment length and residual stenosis were higher following DES
implant in the ST group. Half of the overall lesions received sirolimus-eluting- (50.2%),
paclitaxel-eluting- in 40.3%, everolimus-eluting- in 7%, and zotarolimus-eluting stents in
1.8%. There was no difference between the matched groups with respect to stent
distribution. Preliminary univariable analysis is described in the Table.
Conclusions: These preliminary angiographic characteristics suggest that thrombus
presence and TIMI 0 at presentation, and longer lesion and stented segment with high
residual diameter stenosis post-DES are strong correlates for late ST.
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